5-(氯甲基)-3-(3-甲基苯基)-1,2,4-恶二唑 | 50737-31-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-(氯甲基)-3-(3-甲基苯基)-1,2,4-恶二唑
• 英文名称: 5-(chloromethyl)-3-(m-tolyl)-1,2,4-oxadiazole
• 英文别名: 5-chloromethyl-3-m-tolyl-[1,2,4]oxadiazole；5-chloromethyl-3-m-tolyl-[1,2,4]oxadiazole；5-chloromethyl-3-m-tolyl-1,2,4-oxadiazole；5-(Chloromethyl)-3-(3-methylphenyl)-1,2,4-oxadiazole
• CAS: 50737-31-0
• 化学式: C₁₀H₉ClN₂O
• mdl: MFCD09034175
• 分子量: 208.647
• InChiKey: MWQGYNOPINNJNN-UHFFFAOYSA-N

物化性质

• 沸点：
  340.2±52.0 °C(Predicted)
• 密度：
  1.242±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  5-(氯甲基)-3-(3-甲基苯基)-1,2,4-恶二唑 在 盐酸 、 potassium carbonate 作用下， 以 乙醇 、 丙酮 为溶剂， 生成 1,3-Dipropyl-8-[4-(3-m-tolyl-[1,2,4]oxadiazol-5-ylmethoxy)-phenyl]-3,7-dihydro-purine-2,6-dione
  参考文献：
  名称：

  The discovery of a selective, high affinity A2B adenosine receptor antagonist for the potential treatment of asthma

  摘要：

  Adenosine has been suggested to play a role in asthma, possibly via activation of A(2B) adenosine receptors on mast cells and other pulmonary cells. We describe our initial efforts to discover a xanthine based selective A(2B) AdoR antagonist that resulted in the discovery of CVT-5440, a high affinity A(2B) AdoR antagonist with good selectivity (A(2B) AdoR K-i = 50 nM, selectivity A(1) > 200: A(2A) > 200: A(3) > 167). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.11.044
• 作为产物：
  描述：

  间甲基苯腈 在 盐酸羟胺 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 1,2-二氯乙烷 为溶剂， 生成 5-(氯甲基)-3-(3-甲基苯基)-1,2,4-恶二唑
  参考文献：
  名称：

  作为高亲和力和选择性A2B腺苷受体拮抗剂的新型1,3-二丙基-8-（1-杂芳基甲基-1H-吡唑-4-基）-黄嘌呤衍生物。

  摘要：

  合成了一系列新的1,3-二丙基-8-（1-杂芳基甲基-1H-吡唑-4-基）-黄嘌呤衍生物作为A（2B）-AdoR拮抗剂，并评估了它们与A（2B）的结合亲和力），A（1），A（2A）和A（3）-AdoR。8-（1-（（（3-苯基-1,2,4-恶二唑-5-基）甲基）-1H-吡唑-4-基）-1,3-二丙基-1H-嘌呤-2,6（ 3H，7H）-二酮（4）对A（2B）-AdoR与A（1），A（2A）和A（3）-AdoRs的亲和力（K（i）= 1 nM）和选择性高（ A（1）/ A（2B），A（2A）/ A（2B）和A（3）/ A（2B）选择性比分别为370、1100和480）。本文介绍了这类新型化合物的合成和SAR。

  DOI：

  10.1016/j.bmcl.2005.10.002

文献信息

• Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
  申请人：Edwards Louise

  公开号：US20050272779A1

  公开（公告）日：2005-12-08

  The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.

  本发明涉及公式I的新化合物，包含该化合物的药物配方，以及利用该化合物预防和/或治疗mGluR5受体介导的疾病的用途。
• Compounds
  申请人：Arora Jalaj

  公开号：US20060122397A1

  公开（公告）日：2006-06-08

  The present invention relates to new compounds of formula I, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

  本发明涉及化合物I的新化合物，其制备过程和其中制备的新中间体，含有该化合物的制药配方以及在治疗中使用该化合物的用途。
• ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
  申请人：Edwards Louise

  公开号：US20080045571A1

  公开（公告）日：2008-02-21

  The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.

  本发明涉及公式I的新化合物，包括含有该化合物的制药配方，以及该化合物在预防和/或治疗mGluR5受体介导的疾病中的使用。
• Phenoxymethyl 1,3-oxazoles and 1,2,4-oxadiazoles as potent and selective agonists of free fatty acid receptor 1 (GPR40)
  作者：Ihor Zahanich、Ivan Kondratov、Vasyl Naumchyk、Yuri Kheylik、Maxim Platonov、Sergey Zozulya、Mikhail Krasavin

  DOI：10.1016/j.bmcl.2015.06.018

  日期：2015.8

  A screening hit that showed a weak (EC50 = 18 mu M), partial agonistic effect on GPR40 was used a prototype for expedited hit expansion effort using a set of advanced building blocks. The latter yielded several 1,3-oxazoles and 1,2,4-oxadiazoles with significantly improved potency (best EC50 = 0.058 mu M). The lead compounds in each chemotype showed a very good ADME profile (aqueous solubility, plasma protein binding, microsomal stability and membrane permeability) and no appreciable inhibition of key cytochromes P450. The compounds reported are significant new starting points for further preclinical development of future diabetic agents with a mechanism of action for which a first-in-class agent is yet to be approved. (C) 2015 Elsevier Ltd. All rights reserved.
• New GABA-modulating 1,2,4-oxadiazole derivatives and their anticonvulsant activity
  作者：Hans-Joachim Lankau、Klaus Unverferth、Christian Grunwald、Helge Hartenhauer、Kristina Heinecke、Katrin Bernöster、Rita Dost、Ute Egerland、Chris Rundfeldt

  DOI：10.1016/j.ejmech.2006.12.022

  日期：2007.6

  A series of 3- and 5-aryl-1,2,4-oxadiazole derivatives were prepared and tested for anticonvulsant activity in a variety of models. These 1,2,4oxadiazoles exhibit considerable activity in both pentylenetetrazole (PTZ) and maximal electroshock seizure (MES) models. Compound 10 was protective in the PTZ model in rats with an oral ED50 of 25.5 mg/kg and in the MES model in rats with an oral ED50 Of 14.6 mg/kg. Neurotoxicity (rotarod) was observed with an ED50 Of 335 mg/kg. We found several oxadiazoles that acted as selective GABA potentiating compounds with no interaction to the benzodiazepine binding site. (c) 2007 Elsevier Masson SAS. All rights reserved.